Key facts
- Dolinnov’s last known valuation is $45.0M (Feb 2025).
- It has raised $6.3M; the latest was Early Stage VC ($23.6M) in Mar 2026.
- Notable investors include Bpifrance, Alix Pradère, Business & Innovation Center, University of Montpellier.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Dolinnov
- ·The full record, as it builds
Funding rounds
No funding rounds for Dolinnov are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dolinnov
Developer of pain management therapy designed to transform the lives of patients by delivering services for complex and unbearable conditions. The company offers a therapeutic strategy utilizing a Lipid antisense oligonucleotide to target a regulator at the dorsal root ganglion and a therapeutic target in chronic pain, acting through the regulation of the pump to modulate pain signaling pathways, enabling research pain and pharmaceutical industry to research treatments for serious diseases in areas with medical needs and to ensure these services reach the patients.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2024
- Employees
- 6
- Website
- dolinnov.com/
- Ownership
- Privately Held (backing)
Dolinnov doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dolinnov shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dolinnov in its N-PORT filings yet. We sweep new filings monthly.